Next Article in Journal
Flavivirus Entry Receptors: An Update
Next Article in Special Issue
Gene Therapy Strategies to Exploit TRIM Derived Restriction Factors against HIV-1
Previous Article in Journal
Replication Cycle and Molecular Biology of the West Nile Virus
Previous Article in Special Issue
Stem-Cell-Based Gene Therapy for HIV Infection
Viruses 2014, 6(1), 54-68; doi:10.3390/v6010054

CCR5 as a Natural and Modulated Target for Inhibition of HIV

1,*  and 2,3
1 Calimmune, Inc., Los Angeles, California, CA 90024, USA 2 Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, German Red Cross Blood Service Baden-Württemberg-Hessen, 68167 Mannheim, Germany 3 Cellex GmbH, 01307 Dresden, Germany
* Author to whom correspondence should be addressed.
Received: 2 September 2013 / Revised: 2 December 2013 / Accepted: 11 December 2013 / Published: 30 December 2013
(This article belongs to the Special Issue Gene Therapy for Retroviral Infections)
View Full-Text   |   Download PDF [286 KB, uploaded 12 May 2015]   |  


Human immunodeficiency virus type 1 (HIV-1) infection of target cells requires CD4 and a co-receptor, predominantly the chemokine receptor CCR5. CCR5-delta32 homozygosity results in a truncated protein providing natural protection against HIV infection—this without detrimental effects to the host—and transplantation of CCR5-delta32 stem cells in a patient with HIV (“Berlin patient”) achieved viral eradication. As a more feasible approach gene-modification strategies are being developed to engineer cellular resistance to HIV using autologous cells. We have developed a dual therapeutic anti-HIV lentiviral vector (LVsh5/C46) that down-regulates CCR5 and inhibits HIV-1 fusion via cell surface expression of the gp41-derived peptide, C46. This construct, effective against multiple strains of both R5- and X4-tropic HIV-1, is being tested in Phase I/II trials by engineering HIV-resistant hematopoietic cells.
Keywords: CCR5; C46; gene therapy; HIV; stem cell transplantation CCR5; C46; gene therapy; HIV; stem cell transplantation
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
MDPI and ACS Style

Burke, B.P.; Boyd, M.P.; Impey, H.; Breton, L.R.; Bartlett, J.S.; Symonds, G.P.; Hütter, G. CCR5 as a Natural and Modulated Target for Inhibition of HIV. Viruses 2014, 6, 54-68.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert